What is it about?
This study reported two data sets from two Phase II studies. . The first study had patients with moderate-to-severe asthma take Breezhaler in high or medium-dose as a once-a-day treatment or a twice-a-day high dose treatment of a different inhaler. The result found that the Breezhaler patients were more than 10% likely to achieve near-normal lung volume. The second study compared medium-dose Breehaler to placebo in patients with mild-to-moderate asthma. 48.4% of those receiving the treatment achieve near lung function compared to 6.7% of the placebo.
Featured Image
Photo by Almos Bechtold on Unsplash
Why is it important?
The use of ultra-long-acting beta-adrenoceptors agonist allows for a once-daily treatment which can improve adherence and compliance improving treatment outcomes. Proving a novel treatment has better efficacy and good safety compare to the standard of care is a step towards improving care options for those living with asthma.
Perspectives
The results from these two studies show the effectiveness and safety of this convenient once-daily treatment. This can create new opportunities for those impact by asthma to achieve an effective and sustainable care plan.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma, September 2019, European Respiratory Society (ERS),
DOI: 10.1183/13993003.congress-2019.pa2539.
You can read the full text:
Resources
Contributors
The following have contributed to this page
